Medium-Term Weight Loss and Remission of Comorbidities Following Endoscopic Sleeve Gastroplasty: a Systematic Review and Meta-analysis.
Matyas FehervariMichael G FadelLaith Omar Khalaf AlghazawiBibek DasMaría Rita Rodríguez-LunaSilvana PerrettaAndrew WanHutan AshrafianPublished in: Obesity surgery (2023)
This systematic review and meta-analysis aimed to determine the short- and medium-term weight loss outcomes and comorbidity resolution following endoscopic sleeve gastroplasty. Our search identified 35 relevant studies containing data from 7525 patients. Overall, pooled short-term (12 months) total weight loss (TWL) was 16.2% (95% CI 13.1-19.4%) in 23 studies (n = 5659). Pooled medium-term TWL was 15.4% (95% CI 13.7-17.2%) in 10 studies (n = 4040). Diabetes resolution was 55.4% (95% CI 46-64%), hypertension resolution was 62.8% (95% CI 43-82%), dyslipidaemia resolution was 56.3% (95% CI 49-63%), and obstructive sleep apnoea resolution was 51.7% (95% CI 16.2-87.3%) in four studies (n = 480). This pooled analysis demonstrates that ESG can induce durable weight loss and resolution of obesity-associated comorbidities in patients with moderate obesity.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- single molecule
- glycemic control
- gastric bypass
- case control
- type diabetes
- preterm infants
- end stage renal disease
- weight gain
- newly diagnosed
- metabolic syndrome
- ultrasound guided
- chronic kidney disease
- insulin resistance
- gestational age
- obese patients
- ejection fraction
- machine learning
- physical activity
- prognostic factors
- adipose tissue
- big data
- clinical trial
- sleep quality
- depressive symptoms
- open label
- deep learning
- skeletal muscle
- ulcerative colitis